Codexis Partners with Pharma Firm for siRNA Production
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy CDXS?
Source: stocktwits
- Partnership Agreement: Codexis has entered into an agreement with a pharmaceutical company to produce 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis platform, which will support the preclinical development of a therapeutic candidate for cardiovascular conditions, showcasing the company's technological edge in RNA drug production.
- Surge in Revenue Expectations: Codexis is expected to release its Q4 earnings next week, with Wall Street forecasting a 67% revenue increase to $35.8 million, reflecting strong market demand for its products and potentially improving the company's financial outlook.
- Collaboration with Axolabs: The partnership with Axolabs aims to evaluate the ECO Synthesis platform, which could pave the way for future licensing opportunities and broader adoption of RNA manufacturing technology, enhancing competitive positioning in the market.
- Shift in Market Sentiment: Following the latest announcement, Stocktwits users shifted their sentiment on CDXS from neutral to bullish, indicating increased confidence in Codexis's growth potential, despite the stock having declined over 36% this year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CDXS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CDXS
Wall Street analysts forecast CDXS stock price to rise
5 Analyst Rating
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.250
Low
2.00
Averages
6.00
High
11.00
Current: 1.250
Low
2.00
Averages
6.00
High
11.00
No data
About CDXS
Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Codexis to Announce Q4 Earnings on March 11
- Earnings Announcement Schedule: Codexis is set to release its Q4 earnings on March 11 after market close, with market participants keenly awaiting the results, which are expected to influence stock performance.
- EPS Expectations: Analysts forecast an EPS of -$0.04, representing a 69.2% year-over-year improvement, indicating significant potential for enhanced profitability for the company.
- Revenue Growth Forecast: The revenue estimate stands at $35.83 million, reflecting a 67.0% year-over-year increase, showcasing strong market demand and sales growth that could bolster investor confidence.
- Historical Performance Insight: Historical financial data indicates that Codexis has shown gradual improvement over recent quarters, and if this earnings report meets expectations, it will further solidify its market position in the biotechnology sector.
See More
Codexis Partners with Pharma Firm for siRNA Production
- Partnership Agreement: Codexis has entered into an agreement with a pharmaceutical company to produce 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis platform, which will support the preclinical development of a therapeutic candidate for cardiovascular conditions, showcasing the company's technological edge in RNA drug production.
- Surge in Revenue Expectations: Codexis is expected to release its Q4 earnings next week, with Wall Street forecasting a 67% revenue increase to $35.8 million, reflecting strong market demand for its products and potentially improving the company's financial outlook.
- Collaboration with Axolabs: The partnership with Axolabs aims to evaluate the ECO Synthesis platform, which could pave the way for future licensing opportunities and broader adoption of RNA manufacturing technology, enhancing competitive positioning in the market.
- Shift in Market Sentiment: Following the latest announcement, Stocktwits users shifted their sentiment on CDXS from neutral to bullish, indicating increased confidence in Codexis's growth potential, despite the stock having declined over 36% this year.
See More
Codexis Partners with Pharma Company for siRNA Manufacturing Agreement
- Agreement Signed: Codexis has entered into an agreement with an innovative pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis platform, supporting preclinical development for a cardiovascular therapeutic candidate, marking a significant application of its technology for large-scale production.
- Technology Advantage: The ECO Synthesis platform is designed for efficient, scalable, and high-fidelity production of complex siRNA therapeutics, addressing the increasing manufacturing demands as RNA therapeutics transition from rare diseases to larger indications, showcasing Codexis's capability to meet evolving requirements.
- Market Opportunity Expansion: CEO Alison Moore highlighted that this partnership represents an important entry point into a high-volume market opportunity, illustrating the company's growth path as it continues to expand partnerships and position the platform for potential commercial-scale applications.
- Production Capacity Enhancement: With ECO Synthesis, Codexis can achieve efficient scale-up while maintaining product consistency, which is expected to drive growth in its market share within the RNAi therapeutics sector, meeting the rising manufacturing demands.
See More
CODEXIS ENTERS INTO AGREEMENT FOR 50 G SIRNA PRODUCTION USING ECO SYNTHESIS® MANUFACTURING PLATFORM
- Agreement Overview: Codexis has signed an agreement to manufacture 50 grams of its EcoSYNTHESIS® platform.
- Purpose of Manufacturing: The manufacturing will support the development and production of innovative solutions in biotechnology.
See More
Codexis Partners with Axolabs to Evaluate RNA Manufacturing Platform
- Partnership Agreement: Codexis and Axolabs have signed an agreement for Axolabs to evaluate Codexis' ECO Synthesis Manufacturing Platform, aimed at enhancing the efficient manufacturing of RNA therapeutics, which is expected to significantly improve market access capabilities.
- Technological Innovation: The platform utilizes enzymatic synthesis technology, enabling more sustainable and cost-effective production to meet large-scale manufacturing demands, thereby enhancing both companies' competitiveness in the nucleic acid therapeutics sector.
- Market Potential: Codexis CEO Alison Moore stated that this collaboration will expand the reach of the ECO Synthesis Manufacturing Platform, helping to meet the rapidly growing demand for nucleic acid drugs and potentially paving the way for future licensing discussions.
- Industry Leadership: The combination of Axolabs' technological leadership and Codexis' innovative capabilities reinforces both companies' commitment to providing high-quality oligonucleotide medicines globally, driving the industry towards more efficient manufacturing models.
See More
Codexis Partners with Axolabs to Enhance RNA Manufacturing with ECO Synthesis Platform
- Partnership Agreement: Codexis and Axolabs have entered into an agreement for Axolabs to evaluate Codexis' ECO Synthesis Manufacturing Platform, marking a strategic collaboration in efficient RNA manufacturing that is expected to pave the way for future licensing discussions and broader platform adoption.
- Innovation Potential: Axolabs' Senior Director of Operations noted that this technology could be pivotal for large-scale manufacturing of therapeutic oligonucleotides, enabling more sustainable and cost-effective production, which aligns with market demands for high-quality drugs.
- Market Expansion Strategy: Codexis CEO Alison Moore emphasized the mission to expand the reach of the ECO Synthesis Manufacturing Platform through collaborations with leading CDMOs, thereby enhancing the company's competitive position in the rapidly growing RNA therapeutics market.
- Global Drug Accessibility: This collaboration not only reinforces the commitment of both Codexis and Axolabs to excellence but also aims to enhance global access to high-quality oligonucleotide-based medicines, addressing the increasing market demand.
See More
Codexis to Announce Q4 Earnings on March 11
- Earnings Announcement Schedule: Codexis is set to release its Q4 earnings on March 11 after market close, with market participants keenly awaiting the results, which are expected to influence stock performance.
- EPS Expectations: Analysts forecast an EPS of -$0.04, representing a 69.2% year-over-year improvement, indicating significant potential for enhanced profitability for the company.
- Revenue Growth Forecast: The revenue estimate stands at $35.83 million, reflecting a 67.0% year-over-year increase, showcasing strong market demand and sales growth that could bolster investor confidence.
- Historical Performance Insight: Historical financial data indicates that Codexis has shown gradual improvement over recent quarters, and if this earnings report meets expectations, it will further solidify its market position in the biotechnology sector.
See More
Codexis Partners with Pharma Firm for siRNA Production
- Partnership Agreement: Codexis has entered into an agreement with a pharmaceutical company to produce 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis platform, which will support the preclinical development of a therapeutic candidate for cardiovascular conditions, showcasing the company's technological edge in RNA drug production.
- Surge in Revenue Expectations: Codexis is expected to release its Q4 earnings next week, with Wall Street forecasting a 67% revenue increase to $35.8 million, reflecting strong market demand for its products and potentially improving the company's financial outlook.
- Collaboration with Axolabs: The partnership with Axolabs aims to evaluate the ECO Synthesis platform, which could pave the way for future licensing opportunities and broader adoption of RNA manufacturing technology, enhancing competitive positioning in the market.
- Shift in Market Sentiment: Following the latest announcement, Stocktwits users shifted their sentiment on CDXS from neutral to bullish, indicating increased confidence in Codexis's growth potential, despite the stock having declined over 36% this year.
See More
Codexis Partners with Pharma Company for siRNA Manufacturing Agreement
- Agreement Signed: Codexis has entered into an agreement with an innovative pharmaceutical company to manufacture 50 grams of small interfering RNA (siRNA) using its proprietary ECO Synthesis platform, supporting preclinical development for a cardiovascular therapeutic candidate, marking a significant application of its technology for large-scale production.
- Technology Advantage: The ECO Synthesis platform is designed for efficient, scalable, and high-fidelity production of complex siRNA therapeutics, addressing the increasing manufacturing demands as RNA therapeutics transition from rare diseases to larger indications, showcasing Codexis's capability to meet evolving requirements.
- Market Opportunity Expansion: CEO Alison Moore highlighted that this partnership represents an important entry point into a high-volume market opportunity, illustrating the company's growth path as it continues to expand partnerships and position the platform for potential commercial-scale applications.
- Production Capacity Enhancement: With ECO Synthesis, Codexis can achieve efficient scale-up while maintaining product consistency, which is expected to drive growth in its market share within the RNAi therapeutics sector, meeting the rising manufacturing demands.
See More
CODEXIS ENTERS INTO AGREEMENT FOR 50 G SIRNA PRODUCTION USING ECO SYNTHESIS® MANUFACTURING PLATFORM
- Agreement Overview: Codexis has signed an agreement to manufacture 50 grams of its EcoSYNTHESIS® platform.
- Purpose of Manufacturing: The manufacturing will support the development and production of innovative solutions in biotechnology.
See More
Codexis Partners with Axolabs to Evaluate RNA Manufacturing Platform
- Partnership Agreement: Codexis and Axolabs have signed an agreement for Axolabs to evaluate Codexis' ECO Synthesis Manufacturing Platform, aimed at enhancing the efficient manufacturing of RNA therapeutics, which is expected to significantly improve market access capabilities.
- Technological Innovation: The platform utilizes enzymatic synthesis technology, enabling more sustainable and cost-effective production to meet large-scale manufacturing demands, thereby enhancing both companies' competitiveness in the nucleic acid therapeutics sector.
- Market Potential: Codexis CEO Alison Moore stated that this collaboration will expand the reach of the ECO Synthesis Manufacturing Platform, helping to meet the rapidly growing demand for nucleic acid drugs and potentially paving the way for future licensing discussions.
- Industry Leadership: The combination of Axolabs' technological leadership and Codexis' innovative capabilities reinforces both companies' commitment to providing high-quality oligonucleotide medicines globally, driving the industry towards more efficient manufacturing models.
See More
Codexis Partners with Axolabs to Enhance RNA Manufacturing with ECO Synthesis Platform
- Partnership Agreement: Codexis and Axolabs have entered into an agreement for Axolabs to evaluate Codexis' ECO Synthesis Manufacturing Platform, marking a strategic collaboration in efficient RNA manufacturing that is expected to pave the way for future licensing discussions and broader platform adoption.
- Innovation Potential: Axolabs' Senior Director of Operations noted that this technology could be pivotal for large-scale manufacturing of therapeutic oligonucleotides, enabling more sustainable and cost-effective production, which aligns with market demands for high-quality drugs.
- Market Expansion Strategy: Codexis CEO Alison Moore emphasized the mission to expand the reach of the ECO Synthesis Manufacturing Platform through collaborations with leading CDMOs, thereby enhancing the company's competitive position in the rapidly growing RNA therapeutics market.
- Global Drug Accessibility: This collaboration not only reinforces the commitment of both Codexis and Axolabs to excellence but also aims to enhance global access to high-quality oligonucleotide-based medicines, addressing the increasing market demand.
See More
